Q4 2024 Zealand Pharma A/S Earnings Call Transcript
Key Points
- Zealand Pharma AS (ZLDPF) reported significant clinical advancements in their obesity pipeline, particularly with petrelintide and survodutide.
- The company has a strong cash position of DKK9 billion, which is DKK7.4 billion higher than the previous year, enabling further investment in R&D.
- Enrollment for the ZUPREME-1 Phase 2b trial with petrelintide has been faster than anticipated, indicating strong interest and progress.
- Zealand Pharma AS (ZLDPF) is committed to advancing its rare disease programs, including congenital hyperinsulinism and short bowel syndrome.
- The company has launched a dedicated sustainability strategy, focusing on responsible operations and reducing greenhouse gas emissions.
- GLP-1-based therapies, a focus area for Zealand Pharma AS (ZLDPF), are associated with gastrointestinal adverse events, leading to high discontinuation rates.
- The company received a complete response letter from the US FDA for glepaglutide, requiring an additional Phase 3 trial for approval.
- Operating expenses are expected to significantly increase in 2025, ranging from DKK2.0 billion to DKK2.5 billion, due to expanded R&D efforts.
- There is uncertainty regarding the timing of partnerships for petrelintide, with no specific guidance provided.
- The company faces challenges in the competitive obesity market, with the need for differentiation in their treatment options.
/- -
Welcome and thank you for joining us today to discuss Zealand Pharma's results for the full year 2024. You can also find the related company announcement and annual report on our website at zealandpharma.com.
As described on slide two, I caution listeners that we, during this call, will be making forward-looking statements that are subject to risks and uncertainties.
Turning to slide three and today's agenda, with me are the following members of Zealand Pharma's management team: Adam Steensberg, President and Chief Executive Officer; Henriette Wennicke, Chief Financial Officer; David Kendall, Chief Medical Officer. All speakers will be available for the Q&A session along with Eric Cox, Chief Commercial Officer.
Moving to slide four, I will turn the call over to Adam Steensberg, President and CEO. Adam?
- /
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
